09/03/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 9/3/2020. This four-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the cobas SARS-CoV-2 & Influenza A/B assay. Testing is to be conducted on specimens from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. (PDF)
.png)
No hay comentarios:
Publicar un comentario